Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is developing differentiated products designed to bridge critical gaps in current acute and chronic anticoagulation management for rare and high-risk patient populations.

This fireside chat was recorded during the Lytham Partners 2026 Investor Healthcare Summit.